Hobbs Group Advisors LLC Purchases 1,294 Shares of Johnson & Johnson $JNJ

Hobbs Group Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 71.9% during the second quarter, HoldingsChannel.com reports. The fund owned 3,093 shares of the company’s stock after acquiring an additional 1,294 shares during the period. Hobbs Group Advisors LLC’s holdings in Johnson & Johnson were worth $473,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson in the 1st quarter worth $218,000. GAMMA Investing LLC increased its holdings in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after buying an additional 14,118 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Johnson & Johnson by 6.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company’s stock worth $281,734,000 after buying an additional 107,009 shares during the last quarter. Finally, Blodgett Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 2.2% in the 1st quarter. Blodgett Wealth Advisors LLC now owns 4,894 shares of the company’s stock worth $812,000 after buying an additional 106 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Bank of America increased their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group set a $198.00 target price on shares of Johnson & Johnson in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $192.94.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $190.88 on Tuesday. The firm has a market cap of $459.71 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $178.88 and its two-hundred day simple moving average is $163.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.